Do analysts prefer PHIO or GLMD?

Phio Pharmaceuticals presently has a consensus target price of $14.00, suggesting a potential upside of 1,161.26%. Given Phio Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Phio Pharmaceuticals is more favorable than Galmed Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Phio Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Galmed Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation and earnings, PHIO or GLMD?

Phio Pharmaceuticals is trading at a lower price-to-earnings ratio than Galmed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Phio Pharmaceuticals N/A N/A -$8.70M -$1.38 N/A Galmed Pharmaceuticals N/A N/A -$10.31M -$1.24 N/A

Is PHIO or GLMD more profitable?

Galmed Pharmaceuticals' return on equity of -29.43% beat Phio Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Phio Pharmaceuticals N/A -77.34% -70.87% Galmed Pharmaceuticals N/A -29.43% -26.00%

Do analysts rate GLMD or GOVX?

GeoVax Labs has a consensus target price of $150.00, suggesting a potential upside of 7,181.55%. Given GeoVax Labs' stronger consensus rating and higher possible upside, analysts clearly believe GeoVax Labs is more favorable than Galmed Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Galmed Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 GeoVax Labs 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Is GLMD or GOVX more profitable?

Galmed Pharmaceuticals' return on equity of -29.43% beat GeoVax Labs' return on equity. Company Net Margins Return on Equity Return on Assets Galmed Pharmaceuticals N/A -29.43% -26.00% GeoVax Labs N/A -709.52% -399.33%

Does the media prefer GLMD or GOVX?

In the previous week, GeoVax Labs had 5 more articles in the media than Galmed Pharmaceuticals. MarketBeat recorded 8 mentions for GeoVax Labs and 3 mentions for Galmed Pharmaceuticals. Galmed Pharmaceuticals' average media sentiment score of 0.96 beat GeoVax Labs' score of 0.43 indicating that Galmed Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Galmed Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive GeoVax Labs 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend GLMD or FNCH?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Galmed Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Finch Therapeutics Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable valuation & earnings, GLMD or FNCH?

Finch Therapeutics Group is trading at a lower price-to-earnings ratio than Galmed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Galmed Pharmaceuticals N/A N/A -$10.31M -$1.24 N/A Finch Therapeutics Group N/A N/A -$74.75M -$8.82 N/A

Is GLMD or FNCH more profitable?

Galmed Pharmaceuticals' return on equity of -29.43% beat Finch Therapeutics Group's return on equity. Company Net Margins Return on Equity Return on Assets Galmed Pharmaceuticals N/A -29.43% -26.00% Finch Therapeutics Group N/A -69.14% -26.92%

Do analysts rate LIAN or GLMD?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score LianBio 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Galmed Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings and valuation, LIAN or GLMD?

Galmed Pharmaceuticals is trading at a lower price-to-earnings ratio than LianBio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio LianBio N/A N/A -$110.29M -$0.81 N/A Galmed Pharmaceuticals N/A N/A -$10.31M -$1.24 N/A

Is LIAN or GLMD more profitable?

Galmed Pharmaceuticals' return on equity of -29.43% beat LianBio's return on equity. Company Net Margins Return on Equity Return on Assets LianBio N/A -33.17% -30.19% Galmed Pharmaceuticals N/A -29.43% -26.00%

Do analysts recommend GLMD or APRE?

Aprea Therapeutics has a consensus target price of $4.07, indicating a potential upside of 355.60%. Given Aprea Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Aprea Therapeutics is more favorable than Galmed Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Galmed Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Aprea Therapeutics 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40

Galmed Pharmaceuticals (GLMD) Competitors

$0.75 +0.08 (+11.23%)

Closing price 04:00 PM Eastern

Extended Trading

$0.72 -0.03 (-4.46%)

As of 06:43 PM Eastern

Compare

GLMD vs. PHIO, GOVX, FNCH, LIAN, and APRE

Should you buy Galmed Pharmaceuticals stock or one of its competitors? MarketBeat compares Galmed Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Galmed Pharmaceuticals include Phio Pharmaceuticals (PHIO), GeoVax Labs (GOVX), Finch Therapeutics Group (FNCH), LianBio (LIAN), and Aprea Therapeutics (APRE). These companies are all part of the "pharmaceutical products" industry.

How does Galmed Pharmaceuticals compare to Phio Pharmaceuticals?

Phio Pharmaceuticals (NASDAQ:PHIO) and Galmed Pharmaceuticals (NASDAQ:GLMD) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, media sentiment, risk, dividends and earnings.

Phio Pharmaceuticals is trading at a lower price-to-earnings ratio than Galmed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phio Pharmaceuticals	N/A	N/A	-$8.70M	-$1.38	N/A
Galmed Pharmaceuticals	N/A	N/A	-$10.31M	-$1.24	N/A

Galmed Pharmaceuticals' return on equity of -29.43% beat Phio Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Phio Pharmaceuticals	N/A	-77.34%	-70.87%
Galmed Pharmaceuticals	N/A	-29.43%	-26.00%

Phio Pharmaceuticals presently has a consensus target price of $14.00, suggesting a potential upside of 1,161.26%. Given Phio Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Phio Pharmaceuticals is more favorable than Galmed Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phio Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Galmed Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

57.3% of Phio Pharmaceuticals shares are held by institutional investors. Comparatively, 76.1% of Galmed Pharmaceuticals shares are held by institutional investors. 0.9% of Phio Pharmaceuticals shares are held by insiders. Comparatively, 19.8% of Galmed Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Phio Pharmaceuticals has a beta of 0.84, meaning that its share price is 16% less volatile than the broader market. Comparatively, Galmed Pharmaceuticals has a beta of 0.62, meaning that its share price is 38% less volatile than the broader market.

In the previous week, Galmed Pharmaceuticals had 2 more articles in the media than Phio Pharmaceuticals. MarketBeat recorded 3 mentions for Galmed Pharmaceuticals and 1 mentions for Phio Pharmaceuticals. Galmed Pharmaceuticals' average media sentiment score of 0.96 beat Phio Pharmaceuticals' score of 0.94 indicating that Galmed Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Phio Pharmaceuticals	Positive
Galmed Pharmaceuticals	Positive

Summary

Galmed Pharmaceuticals beats Phio Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

How does Galmed Pharmaceuticals compare to GeoVax Labs?

Galmed Pharmaceuticals (NASDAQ:GLMD) and GeoVax Labs (NASDAQ:GOVX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, risk, dividends, institutional ownership, media sentiment, profitability and analyst recommendations.

GeoVax Labs has a consensus target price of $150.00, suggesting a potential upside of 7,181.55%. Given GeoVax Labs' stronger consensus rating and higher possible upside, analysts clearly believe GeoVax Labs is more favorable than Galmed Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Galmed Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
GeoVax Labs	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Galmed Pharmaceuticals has a beta of 0.62, indicating that its stock price is 38% less volatile than the broader market. Comparatively, GeoVax Labs has a beta of 3.36, indicating that its stock price is 236% more volatile than the broader market.

In the previous week, GeoVax Labs had 5 more articles in the media than Galmed Pharmaceuticals. MarketBeat recorded 8 mentions for GeoVax Labs and 3 mentions for Galmed Pharmaceuticals. Galmed Pharmaceuticals' average media sentiment score of 0.96 beat GeoVax Labs' score of 0.43 indicating that Galmed Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Galmed Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
GeoVax Labs	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

76.1% of Galmed Pharmaceuticals shares are held by institutional investors. Comparatively, 6.1% of GeoVax Labs shares are held by institutional investors. 19.8% of Galmed Pharmaceuticals shares are held by insiders. Comparatively, 0.6% of GeoVax Labs shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Galmed Pharmaceuticals' return on equity of -29.43% beat GeoVax Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Galmed Pharmaceuticals	N/A	-29.43%	-26.00%
GeoVax Labs	N/A	-709.52%	-399.33%

Galmed Pharmaceuticals has higher earnings, but lower revenue than GeoVax Labs. Galmed Pharmaceuticals is trading at a lower price-to-earnings ratio than GeoVax Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Galmed Pharmaceuticals	N/A	N/A	-$10.31M	-$1.24	N/A
GeoVax Labs	$2.49M	2.87	-$21.47M	-$19.12	N/A

Summary

Galmed Pharmaceuticals beats GeoVax Labs on 7 of the 13 factors compared between the two stocks.

How does Galmed Pharmaceuticals compare to Finch Therapeutics Group?

Galmed Pharmaceuticals (NASDAQ:GLMD) and Finch Therapeutics Group (NASDAQ:FNCH) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, earnings, institutional ownership, valuation, dividends, profitability and media sentiment.

Finch Therapeutics Group is trading at a lower price-to-earnings ratio than Galmed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Galmed Pharmaceuticals	N/A	N/A	-$10.31M	-$1.24	N/A
Finch Therapeutics Group	N/A	N/A	-$74.75M	-$8.82	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Galmed Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Finch Therapeutics Group	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

76.1% of Galmed Pharmaceuticals shares are held by institutional investors. Comparatively, 21.8% of Finch Therapeutics Group shares are held by institutional investors. 19.8% of Galmed Pharmaceuticals shares are held by company insiders. Comparatively, 44.9% of Finch Therapeutics Group shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Galmed Pharmaceuticals' return on equity of -29.43% beat Finch Therapeutics Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Galmed Pharmaceuticals	N/A	-29.43%	-26.00%
Finch Therapeutics Group	N/A	-69.14%	-26.92%

Galmed Pharmaceuticals has a beta of 0.62, meaning that its share price is 38% less volatile than the broader market. Comparatively, Finch Therapeutics Group has a beta of 1.18, meaning that its share price is 18% more volatile than the broader market.

In the previous week, Galmed Pharmaceuticals had 3 more articles in the media than Finch Therapeutics Group. MarketBeat recorded 3 mentions for Galmed Pharmaceuticals and 0 mentions for Finch Therapeutics Group. Galmed Pharmaceuticals' average media sentiment score of 0.96 beat Finch Therapeutics Group's score of 0.00 indicating that Galmed Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Galmed Pharmaceuticals	Positive
Finch Therapeutics Group	Neutral

Summary

Galmed Pharmaceuticals beats Finch Therapeutics Group on 9 of the 11 factors compared between the two stocks.

How does Galmed Pharmaceuticals compare to LianBio?

LianBio (NASDAQ:LIAN) and Galmed Pharmaceuticals (NASDAQ:GLMD) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, risk, valuation, profitability, media sentiment, institutional ownership and dividends.

Galmed Pharmaceuticals is trading at a lower price-to-earnings ratio than LianBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LianBio	N/A	N/A	-$110.29M	-$0.81	N/A
Galmed Pharmaceuticals	N/A	N/A	-$10.31M	-$1.24	N/A

LianBio has a beta of 0.23, meaning that its stock price is 77% less volatile than the broader market. Comparatively, Galmed Pharmaceuticals has a beta of 0.62, meaning that its stock price is 38% less volatile than the broader market.

In the previous week, Galmed Pharmaceuticals had 3 more articles in the media than LianBio. MarketBeat recorded 3 mentions for Galmed Pharmaceuticals and 0 mentions for LianBio. Galmed Pharmaceuticals' average media sentiment score of 0.96 beat LianBio's score of 0.00 indicating that Galmed Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
LianBio	Neutral
Galmed Pharmaceuticals	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LianBio	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Galmed Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Galmed Pharmaceuticals' return on equity of -29.43% beat LianBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LianBio	N/A	-33.17%	-30.19%
Galmed Pharmaceuticals	N/A	-29.43%	-26.00%

74.8% of LianBio shares are owned by institutional investors. Comparatively, 76.1% of Galmed Pharmaceuticals shares are owned by institutional investors. 7.6% of LianBio shares are owned by company insiders. Comparatively, 19.8% of Galmed Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Galmed Pharmaceuticals beats LianBio on 9 of the 11 factors compared between the two stocks.

How does Galmed Pharmaceuticals compare to Aprea Therapeutics?

Galmed Pharmaceuticals (NASDAQ:GLMD) and Aprea Therapeutics (NASDAQ:APRE) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, earnings, dividends, profitability, analyst recommendations, valuation and risk.

Galmed Pharmaceuticals has a net margin of 0.00% compared to Aprea Therapeutics' net margin of -4,405.59%. Galmed Pharmaceuticals' return on equity of -29.43% beat Aprea Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Galmed Pharmaceuticals	N/A	-29.43%	-26.00%
Aprea Therapeutics	-4,405.59%	-61.03%	-50.24%

Galmed Pharmaceuticals has higher earnings, but lower revenue than Aprea Therapeutics. Galmed Pharmaceuticals is trading at a lower price-to-earnings ratio than Aprea Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Galmed Pharmaceuticals	N/A	N/A	-$10.31M	-$1.24	N/A
Aprea Therapeutics	$290K	38.10	-$12.60M	-$1.54	N/A

Galmed Pharmaceuticals has a beta of 0.62, meaning that its share price is 38% less volatile than the broader market. Comparatively, Aprea Therapeutics has a beta of 1.48, meaning that its share price is 48% more volatile than the broader market.

Aprea Therapeutics has a consensus target price of $4.07, indicating a potential upside of 355.60%. Given Aprea Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Aprea Therapeutics is more favorable than Galmed Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Galmed Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Aprea Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

76.1% of Galmed Pharmaceuticals shares are held by institutional investors. Comparatively, 34.2% of Aprea Therapeutics shares are held by institutional investors. 19.8% of Galmed Pharmaceuticals shares are held by insiders. Comparatively, 13.6% of Aprea Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Galmed Pharmaceuticals had 2 more articles in the media than Aprea Therapeutics. MarketBeat recorded 3 mentions for Galmed Pharmaceuticals and 1 mentions for Aprea Therapeutics. Aprea Therapeutics' average media sentiment score of 1.89 beat Galmed Pharmaceuticals' score of 0.96 indicating that Aprea Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Galmed Pharmaceuticals	Positive
Aprea Therapeutics	Very Positive

Summary

Galmed Pharmaceuticals beats Aprea Therapeutics on 8 of the 15 factors compared between the two stocks.

Get Galmed Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GLMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GLMD vs. The Competition

Export

Metric	Galmed Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$4.13M	$3.02B	$6.41B	$12.58B
Dividend Yield	N/A	1.97%	2.75%	5.26%
P/E Ratio	-0.61	17.54	21.25	26.28
Price / Sales	N/A	341.85	561.56	114.71
Price / Cash	N/A	56.31	43.49	56.90
Price / Book	0.26	6.31	10.60	7.33
Net Income	-$10.31M	$75.84M	$3.56B	$337.06M
7 Day Performance	29.91%	3.33%	2.97%	3.43%
1 Month Performance	34.55%	2.06%	6.25%	7.24%
1 Year Performance	-47.30%	32.76%	36.72%	37.97%

Galmed Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GLMD Galmed Pharmaceuticals	1.509 of 5 stars	$0.75 +11.2%	N/A	-50.2%	$4.13M	N/A	N/A	20	News Coverage Short Interest Decrease Gap Up
PHIO Phio Pharmaceuticals	3.643 of 5 stars	$1.08 -0.9%	$14.00 +1,196.3%	-43.0%	$12.66M	N/A	N/A	10
GOVX GeoVax Labs	2.113 of 5 stars	$3.49 -4.1%	$150.00 +4,198.0%	-90.9%	$12.64M	$852.28K	N/A	10	News Coverage Short Interest Increase Gap Down
FNCH Finch Therapeutics Group	N/A	$7.45 flat	N/A	N/A	$11.97M	N/A	N/A	190
LIAN LianBio	N/A	$0.11 +0.1%	N/A	N/A	$11.91M	N/A	N/A	110

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GLMD) was last updated on 5/29/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Galmed Pharmaceuticals (GLMD) Competitors

GLMD vs. PHIO, GOVX, FNCH, LIAN, and APRE

How does Galmed Pharmaceuticals compare to Phio Pharmaceuticals?

Summary

How does Galmed Pharmaceuticals compare to GeoVax Labs?

Summary

How does Galmed Pharmaceuticals compare to Finch Therapeutics Group?

Summary

How does Galmed Pharmaceuticals compare to LianBio?

Summary

How does Galmed Pharmaceuticals compare to Aprea Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GLMD vs. The Competition

Galmed Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Galmed Pharmaceuticals (GLMD) Competitors

GLMD vs. PHIO, GOVX, FNCH, LIAN, and APRE

How does Galmed Pharmaceuticals compare to Phio Pharmaceuticals?

Which has higher valuation and earnings, PHIO or GLMD?

Is PHIO or GLMD more profitable?

Do analysts prefer PHIO or GLMD?

Do institutionals and insiders believe in PHIO or GLMD?

Which has more volatility & risk, PHIO or GLMD?

Does the media refer more to PHIO or GLMD?

Summary

How does Galmed Pharmaceuticals compare to GeoVax Labs?

Do analysts rate GLMD or GOVX?

Which has more risk and volatility, GLMD or GOVX?

Does the media prefer GLMD or GOVX?

Do institutionals & insiders hold more shares of GLMD or GOVX?

Is GLMD or GOVX more profitable?

Which has better earnings & valuation, GLMD or GOVX?

Summary

How does Galmed Pharmaceuticals compare to Finch Therapeutics Group?

Which has preferable valuation & earnings, GLMD or FNCH?

Do analysts recommend GLMD or FNCH?

Do insiders and institutionals believe in GLMD or FNCH?

Is GLMD or FNCH more profitable?

Which has more risk & volatility, GLMD or FNCH?

Does the media prefer GLMD or FNCH?

Summary

How does Galmed Pharmaceuticals compare to LianBio?

Which has better earnings and valuation, LIAN or GLMD?

Which has more risk and volatility, LIAN or GLMD?

Does the media favor LIAN or GLMD?

Do analysts rate LIAN or GLMD?

Is LIAN or GLMD more profitable?

Do institutionals & insiders have more ownership in LIAN or GLMD?

Summary

How does Galmed Pharmaceuticals compare to Aprea Therapeutics?

Is GLMD or APRE more profitable?

Which has stronger valuation and earnings, GLMD or APRE?

Which has more risk and volatility, GLMD or APRE?

Do analysts recommend GLMD or APRE?

Do institutionals & insiders have more ownership in GLMD or APRE?

Does the media favor GLMD or APRE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GLMD vs. The Competition

Galmed Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools